Eurofins Scientific : Q1 2021 Results Presentation

CONFIDENTIAL AND PROPRIETARY - © Eurofins Scientific (Ireland) Ltd, 2021. All rights reserved. This document contains information that is confidential and proprietary to Eurofins Scientific SE and / or its affiliates and is solely for the use of the personnel of Eurofins Scientific SE and all its affiliates. No part of it may be used, circulated, quoted, or reproduced for distribution outside companies belonging to the Eurofins Group. If you are

not the intended recipient of this document, you are hereby notified that the	use,
circulation, quoting,	or reproducing of	this	document is strictly prohibited and	may
be unlawful. Photo	images on this page	are	the copyrighted property of 123RF Limited.
D

Q1 2021 Management Update

Eurofins reports Core Business organic growth close to 10%

in Q1 2021 and 44.3% overall

28 April 2021

www.eurofins.com

Disclaimer

This presentation does not constitute or form part of, and should not be construed as, an offer or invitation to subscribe for or purchase securities in Eurofins Scientific S.E. and neither this document nor anything contained or referred to in it shall form the basis of, or be relied on in connection with, any offer or commitment whatsoever.

The statements made during this presentation or as response to questions during the Question & Answers period that are not historical facts are forward looking statements. Furthermore, estimates and judgements may be made based on market and competitive information available at a certain time. Forward looking statements and estimates represent the judgement of Eurofins Scientific's management and involve risks and uncertainties including, but not limited to, risks associated with the inherent uncertainty of research, product/service development and commercialisation, the impact of competitive products and services, patents and other risk uncertainties, including those detailed from time to time in period reports, including prospectus and annual reports filed by Eurofins Scientific with the Luxembourg Stock Exchange and regulatory authorities, that can cause actual results to differ materially from those projected. Eurofins Scientific expressly disclaims any obligation or intention to release publicly any updates or revisions to any forward looking statement or estimate.

Eurofins provides in the Income Statement certain alternative performance measures (non-IFRS information as "Adjusted Results and Separately Disclosed Items") that excludes certain items because of the nature of these items and the impact they have on the analysis of underlying business performance and trends. (Please refer to description of these terms in the Company's Annual Report). The management believes that providing this information enhances investors' understanding of the company's core operating results and future prospects, consistent with how management measures and forecasts the company's performance, especially when comparing such results to previous periods or objectives and to the performance of our competitors. This information should be considered in addition to, but not in lieu of, information prepared in accordance with IFRS. These APMs are described in more detail in the Consolidated Financial Statements 2020 in Notes 1.27 and 1.28.

2

Key operational highlights

• Eurofins remained very active in fighting the pandemic throughout Q1 2021:
• • Set up very high throughput SARS-CoV-2 NGS1 capacity and won large contracts to support several countries and institutions to monitor and identify the emergence and spread of new Variants of Interest or of Concern
  • Continued its innovation and product launches, particularly around self-testing
  • Continued expansion of the Group's SAFER@WORK™ offering
• Continued cooperation between business lines to share knowledge and enhance cross selling efforts with, as an example, PFAS2 testing becoming of increasing interest for environmental and food industry
• Strong activity across the Group's diverse Drug Discovery portfolio with strong pick-up in discovery programmes in Q1
• Continued reinforcement of the Group's capabilities in Food and Agriproducts Testing:
• • In Europe, with a start-up laboratory in Lodz, Poland, and a new laboratory in Croatia close to Zagreb
  • In the U.S., with strong volume growth across the entire portfolio
  • Launch of Eurofins' new NGS offer for bacterial flora identification
• Environment Testing business in Australia and New Zealand recovered well in Q1 2021. Strong rebound of North American business in late March
• Continued investments in the Group's laboratory network and IT systems
• Consistent with 2020, M&A has remained deprioritised in Q1 2021, as the Group focuses on responding to COVID-19 and investing in the existing business

1 Next Generation Sequencing	3
2 Per- and polyfluoroalkyl substances

Key financial highlights

Revenue, EUR m

1,614

1,142

Q1 2020

Q1 2021

Key Highlights

• Strong revenues in Q1 of EUR 1,614m, +41.3% year-on-year, despite a foreign exchange headwind of -3.7% (Q1 2021 vs. Q1 2020 average FX rates)
• Very strong organic revenue growth1 of 44.3% in Q1 2021 reflecting the significant contribution from COVID-19 related activities and the rapidly accelerating growth of the
  Group's Core Business2
• Despite ongoing lockdown restrictions in many key markets, the Group's Core Business delivered close to 10% organic revenue growth in Q1 2021 (over 11% adjusted for public working days' impact) against a robust comparable trading period in Q1 2020 (Q1 2020 organic growth was 4.1%)
• COVID-19related clinical testing and reagents activities contributed revenues of close to EUR 400m in Q1 2021
• Continued capital management:
• • Repayment of EUR 112m short-term borrowings (Schuldschein and commercial paper) in January
  • Exercise of the make-whole call of its 2022 senior notes, which will result in a reduction in gross indebtedness of EUR 279.2m and a cash outflow of EUR 286.3m

1 Organic growth for a given period (Q1, Q2, Q3, Half Year, Nine Months or Full Year) - non-IFRS measure calculating the growth in revenues during that period between 2 successive years for the same scope of businesses using the same exchange rates (of year Y) but excluding discontinued operations. For the purpose of organic growth calculation for year Y, the relevant scope used is the scope of businesses that have been consolidated in the Group's income statement of the previous financial year (Y-1). Revenue contribution from companies acquired in the course of Y-1 but not consolidated for the full year are adjusted as if they had been consolidated as of 1st January Y-1. All revenues from businesses acquired since 1st January Y are excluded from the calculation.

2 Core Business excludes COVID-19 related clinical testing and reagent revenues

4

COVID-19 related business developments: innovation and product launches

• GSD NovaPrime®, successfully validated for pharynx gargle and saliva samples
• GSD NovaLisa®, a quantitative antibody ELISA kit to measure immune response to COVID-19 and vaccines
• • CE marked serological assay
  • Supports vaccination campaigns by confirming the success of a vaccination and monitoring antibody levels over time
• GSD NovaType II, for the identification of mutations associated with SARS-CoV-2 variants of concern:
• • New kit can detect the N501Y and E484K mutations, common to most Variants Of Concern, and the K417N mutation, specific to B.1.351 first identified in South Africa, with a high sensitivity
  • Results delivered under two hours
• EmpowerDX direct-to-consumerCOVID-19 Home Collection PCR kit, launched on Amazon in the U.S.
• Partnership with Uber in over two dozen U.S. cities to deliver Eurofins' COVID-19 Home Collection PCR Kits
• Low cost at-home PCR testing kits in the UK, facilitating greater access to affordable and accurate PCR testing to support a return to travel
• Home Collection PCR Kits using gargling samples in Germany and Spain
• Large contracts won to provide very high throughput SARS-CoV-2 NGS sequencing capacity, supporting several countries and institutions in their programmes to monitor and identify the spread of new Variants of Interest or of Concern
• Used some biopharma capacity in Core Business for priority COVID-19 therapeutics and vaccine work

5